DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03436199 (ClinicalTrials.gov)	March 29, 2018	12/2/2018	Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment	A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment	Walking Impairment;Multiple Sclerosis	Drug: ADS-5102, 137 mg;Drug: ADS-5102, 274 mg;Other: Placebo	Adamas Pharmaceuticals, Inc.	NULL	Completed	18 Years	70 Years	All	594	Phase 3	United States;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03436199
(ClinicalTrials.gov)

March 29, 2018

12/2/2018

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment

Walking Impairment;Multiple Sclerosis

Drug: ADS-5102, 137 mg;Drug: ADS-5102, 274 mg;Other: Placebo

Adamas Pharmaceuticals, Inc.

NULL

Completed

18 Years

70 Years

All

594

Phase 3

United States;Canada